PVLA — PALVELLA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583648 ·
Last close
$145.75
Market Cap
$2.10B
52W High
$161.38
52W Low
$100.00
ADV30
202,754
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -21,405,000 | -21,870,000 | 253,510,000 | 187,803,000 | 36,643,000 |
| Mar 2026 | 0 | — | -14,855,000 | -15,767,000 | 263,759,000 | 206,394,000 | 31,446,000 |
| Dec 2025 | 0 | — | -11,304,000 | -12,714,000 | 59,559,000 | 57,982,000 | 31,576,000 |
| Sep 2025 | 0 | — | -10,177,000 | -11,345,000 | 66,937,000 | 63,567,000 | 28,255,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,513,000
Investing CF
$-62,472,000
Financing CF
$216,204,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-173,087,000
Inventory
—
Receivables
$0
ST Investments
$62,781,000
EBIT TTM
$-54,100,000
Pretax Income TTM
$-61,696,000
Interest Exp TTM
$7,596,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,602,000 | -41,715,000 | 59,559,000 | 31,576,000 | — | -25,006,000 |
| Dec 2024 | 0 | -14,095,000 | -17,434,000 | 88,234,000 | 25,627,000 | — | -10,840,000 |
| Dec 2023 | 0 | -11,869,000 | 18,691,000 | 7,548,000 | 11,428,000 | — | -13,703,000 |
| Dec 2022 | 0 | -18,040,000 | -27,552,000 | 16,524,000 | 39,698,000 | — | -14,840,000 |
TTM Snapshot
Revenues TTM
$29,701,000
NetIncome TTM
$-38,526,000
OpCashFlow TTM
$0
Assets (Latest)
$153,560,000
Forward EPS
$-7.50
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $150.00 · spot: $145.75 · call volume: 84 · put volume: 93Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $2.09B | $32.32 | — |
| HCM | HUTCHMED (China) Ltd | $2.12B | $12.18 | — |
| BHVN | Biohaven Ltd. | $2.07B | $13.68 | — |
| GRFS | Grifols SA | $2.06B | $7.99 | — |
| ZBIO | Zenas BioPharma, Inc. | $2.06B | $31.65 | — |
News headlines (Yahoo Finance, 1h cache)
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
2026-08-16 16:01 · Yahoo
Palvella (PVLA) Q2 2026 Earnings Call Transcript
2026-08-11 17:16 · Yahoo
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
2026-08-08 11:10 · Yahoo
Palvella Therapeutics Q2 Earnings Call Highlights
2026-08-04 17:04 · Yahoo
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
2026-07-30 11:30 · Yahoo
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN
2026-07-15 14:01 · Yahoo
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
2026-06-29 11:30 · Yahoo
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
2026-06-27 16:31 · Yahoo
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
2026-06-22 12:49 · Yahoo
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
2026-06-22 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.